Business news from Yahoo
And the W’s just keep on coming for Sorrento Therapeutics (SRNE). Reflecting a major step forward in the advancement of its candidate, STI-6129, a CD38-targeting antibody-drug conjugate (ADC), the company received the all-clear from the FDA to submit an Investigational New Drug (IND) application.Part of the excitement surrounding this announcement is related to the design of the asset itself. STI-6129 was created using SRNE’s unique technology that includes a CD38-specific antibody identified from its fully human G-MAB antibody library, its patented drug payload Duostatin 5 and its site-specific CLOCK conjugation technology.On top of this, the company wants to kick off a Phase 1 multi-center, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis, with the primary goal being the identification of a Phase 2 dose for STI-6129.Commenting on the development for H.C. Wainwright, five-star analyst Raghuram Selvaraju thinks the asset “could constitute a next-generation approach to treatment of AL amyloidosis.”“The prospects for a CD38-targeted approach in this indication appear buttressed by data from a prospective Phase 2 trial of daratumumab, a well-known fully human monoclonal anti-CD38 antibody agent that is already commercially available for the treatment of multiple myeloma (MM) under the trade name DARZALEX... Renal response occurred in 10 of 15 patients (67%) with renal involvement and cardiac response occurred in seven out of 14 patients (50%) with cardiac involvement. In our view, these data bode well for the deployment of an anti-CD38 agent in AL amyloidosis,” Selvaraju added.As approximately 20,000 people are affected by AL amyloidosis in the U.S. alone, the indication represents a niche opportunity for SRNE. With the clinical benefit produced using daratumumab to treat AL amyloidosis serving as a partial proof-of-concept for STI-6129, it’s no wonder the news is promising, in Selvaraju’s opinion.Even though Selvaraju tells clients that the candidate has not been built into his models, he believes the announcement demonstrates “the steadily growing depth and breadth of Sorrento's pipeline.”Based on all of the above, Selvaraju stayed with the bulls. Along with a Buy rating, he kept a $24 price target on the stock. This indicates upside potential of a whopping 369%. (To watch Selvaraju’s track record, click here) What does the rest of the Street think about SRNE’s long-term growth prospects? It has been relatively quiet when it comes to analyst activity, with the stock receiving only one other Buy rating in the last three months. This makes the consensus rating a Moderate Buy. In addition, the $24 average price target matches Selvaraju’s. (See Sorrento stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Is anything about to derail Nvidia’s (NVDA) growth momentum? The GPU leader is enjoying an extended moment in the sun, when just about everything is going its way. An excellent F1Q21 report, the latest highlight, resulted in additional brawn to its ever-bulging share price – by now up 45% since the turn of the year.There’s more to come, argues Needham’s Rajvindra Gill, who calls Nvidia “the only perpetual growth story in semis.” The 5-star analyst has a Buy rating on Nvidia shares, accompanied by a $400 piece target. Expect additional upside of 17%, should the target be met over the next 12 months. (To watch Gill’s track record, click here)COVID-19’s devastating impact has not impeded Nvidia’s forward charge. In fact, as evidenced by the earnings results, it has boosted the narrative for Nvidia’s two main segments – Gaming and Data Center.The stay-at-home economy resulted in a 50% uptick for gaming hours on its GeForce platform. Overall, in the quarter, Gaming revenue (making up 43% of F1Q21 sales) increased year-over-year by 27% to $1.34 billion, beating the Street’s call for $1.31 billion.But the really impressive numbers are reserved for Nvidia’s Data Center. Making up 37% of overall sales, the segment still trails Gaming as Nvidia’s top earner, yet throughout F20 the division had been closing the gap and the most recent showing continued the trend.Data Center revenue came in at $1.14 billion, above the $1.08 billion estimate, exhibiting 80% year-over-year growth and up by 18% from the prior quarter’s results.With the additional purchase of data specialist Mellanox completed, Gill expects “data center strength to continue throughout FY21.”The 5-star analyst commented, “We believe data center, the end-market that we view as NVDA’s biggest growth engine, is experiencing a recovery as hyperscaler sales have ramped the past few quarters and visibility has improved. We expect the competitive dynamics in the data center market will exert pressure on its long-term positioning in this market; however, we believe several industries will transition to AI-based systems faster than before.”The rest of the Street has no bones to pick with the Needham analyst’s assessment. A Strong Buy consensus rating is based on 1 Sell, 3 Holds and a towering 27 Buys. With an average price target of $381 and a change, investors stand to take home about 12% gain, should the target be met over the next 12 months. (See Nvidia stock analysis on TipRanks)Read more: * Micron Is a Strong 5G Play, Says 5-Star Analyst * 3 “Perfect 10” Dividend Stocks That Tick all the Boxes * 3 “Strong Buy” Penny Stocks That Could See Outsized Gains More recent articles from Smarter Analyst: * Google Pay App May Face Anti-Trust Probe In India – Report * 3 “Strong Buy” Biotech Stocks Under $5 With Explosive Upside Potential * Gilead & Arcus Join Forces For 10-Year Cancer Deal, Arcus Down 15% In Pre-Market * Papa John’s U.S. Pizza Sales Jump 33.5%; Shares Pop 7% In Pre-Market
After months without live sports, it looks as though America's favorite pastimes are on the cusp of returning. Reports indicate the MLB is on pace to return sooner rather than later, while the NHL and NBA have also submitted plans to resume their playoffs this summer.Financially, the resurgence of players in arenas may mean the resurgence of players in the stock market as well. Here are four stocks that may be poised for a breakout with the return of live sports.DraftKingsDraftKings Inc (NASDAQ: DKNG) is new to the market, debuting in early April at around $19. Since then, it's climbed over 70% to $33 a share.Much of the hype surrounding DraftKings has to do with continuous pro-gambling legislation being pushed throughout the country. Given the gambling industry's potentially massive contribution to the government, more and more states are entertaining the possibility of legalizing it.More good news for the online fantasy and gambling app is the new trend for people to gamble on non-sporting events, such as the outcome of TV shows like "The Bachelor."Chris Camillo said DraftKings' potential comes as a result of the exponential growth in legality and popularity of online sports gambling.> "I think you can make a case that most states are going to have legalized sports books in the next five, six, seven years. So this is a movement. This is a major, major movement."Prior to the absence of sports, people were betting on games more than ever. The hiatus likely created an immense desire to get back to the action.Penn National Gaming Penn National Gaming (NASDAQ: PENN) is one of the most interesting stocks in the gaming and entertainment industry.Penn operates both brick-and-mortar and online gambling to a plethora of users. It owns 41 facilities, which comprise 50,500 gaming machines, 1,300 table games and 8,800 hotel rooms. Perhaps the most exciting element of Penn National is its recently-inked partnership with Barstool Sports.Barstool Sports has been a leading sports and men's lifestyle blog and podcasting network over the past few years.The agreement between Penn and Barstool paves the way for Penn to be the operator of a Barstool Sports gambling app. Given Barstool's incredible reach and audience (three top 60 podcasts in the U.S.), the app will surely explode on the scene."Penn's got the bigger growth in the future (as compared to other gaming companies on the market)," Jordan Mclain said on the "Dumb Money LIVE" show. "I think they've got a brand they can capitalize on."See Also: Why Penn National And Boyd Could Outperform As US Casinos ReopenGanGan Ltd (NASDAQ: GAN) is an extremely under-the-radar stock that also operates in the sports gaming space. It IPO'd on May 5 at just over $10. The small-cap stock has since risen above the $15 handle, representing about 50% returns in its first month on the market.Gan's core business centers around a subscription revenue model. Its software allows it to take a piece of the action on every bet or gamble for the gaming companies that it works for. Its most notable client is likely FanDuel, an international competitor to DraftKings.One of the company's more notable elements is that it owns a patent on the ability for a casino that has an offline brick-and-mortar presence with an offline loyalty program to merge that with an online loyalty program.In fact, it won a 2018 court case in which it sued for the wrongful usage of this patent, which has further solidified its viability and credibility.According to Camillo, Gan has the potential to be in the right place at the right time with the return of sports."I see Gan as an asymmetric trade on the imminent growth of legalized app-based sports and casino wagering in the U.S.," Camillo said.> "While most investors in this space are focused on DraftKings, FanDuel, MGM, and the soon to be Barstool Sportsbook by Penn National -- GAN's platform software and services solution along with their leadership experience in the sector position them to come out as the real winner in what is likely to grow into a fragmented market of state-licensed casino and sportsbook brands that are equally technology and process deficient "Gan will be able to leverage this patent to work with casinos in developing the aforementioned online loyalty programs, which could be a huge boost. Investors seem to be taking notice of this, along with the general rise of the gambling industry in general, as good signs for Gan.Walt Disney CoDisney (NYSE: DIS), like most of the market, suffered a significant drop in share valuation as a result of the coronavirus pandemic. The stock has dropped roughly 15% in price since the end of February, when it hovered just over the $140 handle.With the resurgence of sports back on the scene in the coming weeks and months, it's plausible to expect the viewership of ESPN to surge. The channel owns rights to multiple NBA and MLB games per week.ESPN's typical programming, which comprises mostly talk shows, will finally be able to recap highlights and statistics from the previous day once again after months of having to cover general topics and trends, such as the NFL's new collective bargaining agreement.Camillo mentioned on the "Dumb Money LIVE" show that Disney looks like a safe play with the return of sports."It's gonna be a net positive for Disney. It's kind of undebatable...I'm comfortable with my Disney position for the long term," he said.See more from Benzinga * These 10 Stocks Have Surged During The Coronavirus Pandemic(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Berkshire Hathaway’s (NYSE: BRK.A) (NYSE:BRK.B) owner Warren Buffett is the most popular investor who built his $89.9 billion net worth by investing in value companies. He was among the few who profited from the 2008 crisis. In the current Covid-19 crisis, he is holding a lot of cash as most companies are not prepared for […]